SCHOTT Pharma stock reaches a 52-week high on Xetra

SCHOTT Pharma stock (ISIN DE000A3ENQ51) was trading at EUR 23.95 on Xetra on September 23, 2026, after the intraday quote reached EUR 24.30, a 52-week high. The latest operating figures show third-quarter revenue of EUR 281.76 million, up 9.87 percent from EUR 256.46 million a year earlier.

Revenue growth reaches 9.87 percent

The quarterly figures were published on August 12, 2026, for the period ended June 30, 2026. According to finanzen.ch, revenue rose from EUR 256.46 million to EUR 281.76 million, while earnings per share declined from EUR 0.30 to EUR 0.26.

That combination matters for the stock. Revenue expanded by EUR 25.30 million, but the lower EPS figure shows that sales growth did not translate into higher per-share earnings in the same quarter.

Analyst target remains above market

On September 15, 2026, JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target. finanzen.net reported that the bank sees earnings growth potential of 14 percent per year through 2029.

The target is EUR 3.15 above the EUR 23.95 quote, equivalent to 13.15 percent. The gap gives the market a clear valuation reference, but the quarterly EPS decline remains an important counterweight to the revenue advance.

Stock stays near yearly peak

The EUR 23.95 quote on September 23, 2026, was 1.44 percent below the session high of EUR 24.30. The narrow distance to the 52-week peak places the recent price performance alongside the company figures, with investors weighing expanding revenue against per-share profitability.

SCHOTT Pharma had a market capitalization of EUR 3,607,220,053 as of September 23, 2026. The stock therefore combines a fresh yearly high with a current market value above EUR 3.6 billion and a quarterly revenue comparison that remains positive.

More news and analyses on SCHOTT Pharma stock